Long-term follow up after switching from original infliximab to an infliximab biosimilar: real-world data

BACKGROUND: Several studies have reported positive efficacy outcomes for patients with inflammatory bowel disease treated with CT-P13, an infliximab biosimilar. Data from follow-up periods longer than 1 year are still scarce. Here, we assessed the long-term efficacy data, loss of response and safety...

Descripción completa

Detalles Bibliográficos
Autores principales: Guerra Veloz, María Fernanda, Belvis Jiménez, María, Valdes Delgado, Teresa, Castro Laria, Luisa, Maldonado Pérez, Belén, Perea Amarillo, Raúl, Merino Bohórquez, Vicente, Caunedo Álvarez, Ángel, Vilches Arenas, Ángel, Argüelles-Arias, Federico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585238/
https://www.ncbi.nlm.nih.gov/pubmed/31258621
http://dx.doi.org/10.1177/1756284819858052

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585238/
https://www.ncbi.nlm.nih.gov/pubmed/31258621
http://dx.doi.org/10.1177/1756284819858052

Ejemplares similares